Curaleaf Holdings, Inc. (OTCMKTS:CURLF) Receives Average Recommendation of “Buy” from Analysts

Shares of Curaleaf Holdings, Inc. (OTCMKTS:CURLF) have received a consensus recommendation of “Buy” from the five analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating, two have assigned a buy rating and two have issued a strong buy rating on the company.

Several equities analysts recently weighed in on CURLF shares. Zacks Research raised shares of Curaleaf from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Canaccord Genuity Group upgraded Curaleaf to a “strong-buy” rating in a report on Thursday, October 9th. Atb Cap Markets upgraded Curaleaf from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 2nd. ATB Capital raised Curaleaf to an “outperform” rating in a research report on Tuesday, December 2nd. Finally, Alliance Global Partners reaffirmed a “buy” rating on shares of Curaleaf in a report on Monday, December 22nd.

Curaleaf Stock Performance

Shares of CURLF stock opened at $2.48 on Friday. The company has a current ratio of 1.47, a quick ratio of 0.71 and a debt-to-equity ratio of 0.96. The firm has a fifty day simple moving average of $2.67 and a two-hundred day simple moving average of $2.39. Curaleaf has a 12 month low of $0.68 and a 12 month high of $5.05. The firm has a market capitalization of $1.68 billion, a PE ratio of -7.75 and a beta of 0.73.

Curaleaf (OTCMKTS:CURLF) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. Curaleaf had a negative net margin of 19.50% and a negative return on equity of 15.57%. Analysts forecast that Curaleaf will post -0.25 EPS for the current fiscal year.

About Curaleaf

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.